Clinical trials: Proton Pump Inhibitors
Healthy Participants
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants.
- Trial name
- NCT06948006
- Testing
- AZD4144, Omeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.
- Trial name
- NCT05826574
- Testing
- Brensocatib, Rifampin, Esomeprazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Healthy Volunteer
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of…
- Trial name
- MT-7117 BA DDI (NCT03688022)
- Testing
- MT-7117, PPI, Acidic beverage
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
GERD
Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of GERD
Prospective, open-label, multi-centre, single arm treatment only trial to evaluate the safety and effectiveness of RefluxStop for the treatment of GERD.
- Trial name
- NCT02759094
- Testing
- Treatment with RefluxStop
- Where
- 4 sites in Hungary, Serbia
- Volunteers
- 50 people
- Sponsor
- Implantica CE Reflux Ltd.
Gastroesophageal Reflux Disease
Esomeprazole in PPI Failures - IMPROVE
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation…
- Trial name
- NCT00272701
- Testing
- Esomeprazole, Other PPI marketed in Sweden
- Where
- 42 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Peptic Ulcer Hemorrhage
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding.
- Trial name
- NCT03362281
- Testing
- Ilaprazole, Omeprazole, Ilaprazole tablet
- Volunteers
- 540 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.
- Trial name
- NCT06417229
- Testing
- BMS-986365, Rabeprazole
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Celgene
Gastrointestinal Disease
Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population
This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.
- Trial name
- ECHO (NCT03118778)
- Where
- China
- Volunteers
- 90,895 people
- Sponsor
- AstraZeneca
Healthy
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV).
- Trial name
- NCT04984525
- Testing
- SYNB1934, SYNB1618
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Synlogic
Gastroesophageal Reflux Disease (GERD)
Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone
Many patients with acid reflux disease do not improve with regular doses of proton pump inhibitors (e.g., omeprazole). The goals of this clinical trial is the to see if taking MARIAL®, in combination with omeprazole, for one…
- Trial name
- GENYAL® (NCT04130659)
- Testing
- MARIAL® + PPI (generic Omeprazole), PPI alone (generic omeprazole), MARIAL® alone
- Where
- 5 sites in Italy, Romania
- Volunteers
- 110 people
- Sponsor
- Nekkar Lab Srl
Healthy Volunteers
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.
- Trial name
- NCT00746733
- Testing
- Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after…
- Trial name
- NCT05468164
- Testing
- Selpercatinib, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Gastroesophageal Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
The aim of the study was to evaluate the effect of 7 days treatment with Pantoprazole 40 mg and 20 mg on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) in clinical…
- Trial name
- PANTHER (NCT00561730)
- Testing
- Pantoprazole
- Where
- 259 sites in Germany
- Volunteers
- 1,995 people
- Sponsor
- Nycomed
Gastric pH Control
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
The purpose of this study is to determine if magnesium pantoprazole 20 mg twice a day (b.i.d.), maintains gastric pH above 4 during a longer percentage of time than magnesium pantoprazole 40 mg once a day (qd).
- Trial name
- NCT01499693
- Testing
- Magnesium Pantoprazole 20 mg, Magnesium Pantoprazole 40 mg
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
Healthy
A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755
This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants.
- Trial name
- NCT07141381
- Testing
- VRN110755, Rabeprazole
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Voronoi, Inc
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
- Trial name
- NCT01390714
- Testing
- E3710
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Healthy
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
- Trial name
- NCT06619314
- Testing
- Calderasib, PPI
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC